Company insider dossier

Seer Inc insider intelligence

SEER filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
22/100

Concentrated distribution

50/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
18 Aug 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • Participation spans 8 named insiders rather than one filing source.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
  • Most filings are awards, derivatives, unpriced common shares, or other securities and remain contextual.
  • The latest qualifying filing is more than 30 days old.
Conviction22Concentrated distribution
Confidence50Developing
Named insiders8participating in the tape
Controlled events3directional common-share events
Acquisition value$0normalized amount
Disposal value$50.4Knormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

2.312.141.971.791.62 Disposal · 18 Aug 2026 · $14.8KAcquisition · 28 Jul 2026 · Not reportedAcquisition · 28 Jul 2026 · Not reportedAcquisition · 28 Jul 2026 · Not reportedAcquisition · 28 Jul 2026 · Not reportedAcquisition · 28 Jul 2026 · Not reportedAcquisition · 28 Jul 2026 · Not reportedDisposal · 8 Jul 2026 · $23.3KDisposal · 20 May 2026 · $12.4KAcquisition · 8 May 2026 · Not reported
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
1.86 USD
One-week move
-4.6%
Four-week move
-8.4%
Fair-value gap
-4.8%
Trend signal
Active
Relative strength
-13.5

Directional balance

Controlled event mix

0.0%acquisition
Acquisition events
0
Disposal events
3
Net value
-$50.4K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

106 Jul
013 Jul
020 Jul
1227 Jul
003 Aug
010 Aug
117 Aug
024 Aug
031 Aug
007 Sep
014 Sep
021 Sep

Named participants

Insider conviction by person

BAZARKO, ANTHONY R.Chief Commercial Officer500 events
GULYANI, MEETADirector500 events
LANGER, ROBERTDirector500 events
MCGUIRE, TERRANCEDirector500 events
RO, ISAACDirector500 events
ROELOFS, NICOLAS H PHDDirector500 events
NISHAR, DIPCHANDDirector281 events
HORN, DAVID R.PRESIDENT & CFO252 events

Evidence quality

Security and transaction context

Common equity10
Equity compensation0
Options and derivatives7
Other securities0

Role architecture

Who is participating

Director13
Finance leadership2
Other executive2

Transaction evidence

Auditable SEER filing ledger

Showing 1 to 17 of 17.

HORN, DAVID R.PRESIDENT & CFO
DisposalCommon equity
7309 sharesClass A Common Stock
$14.8KDirectional evidence
GULYANI, MEETADirector
AcquisitionCommon equity
16500 sharesClass A Common Stock
Not reportedContext evidence
GULYANI, MEETADirector
AcquisitionOptions and derivatives
25000 sharesStock Option (right to buy)
Not reportedContext evidence
LANGER, ROBERTDirector
AcquisitionCommon equity
16500 sharesClass A Common Stock
Not reportedContext evidence
LANGER, ROBERTDirector
AcquisitionOptions and derivatives
25000 sharesStock Option (right to buy)
Not reportedContext evidence
MCGUIRE, TERRANCEDirector
AcquisitionOptions and derivatives
25000 sharesStock Option (right to buy)
Not reportedContext evidence
MCGUIRE, TERRANCEDirector
AcquisitionCommon equity
16500 sharesClass A Common Stock
Not reportedContext evidence
NISHAR, DIPCHANDDirector
AcquisitionOptions and derivatives
25000 sharesStock Option (right to buy)
Not reportedContext evidence
NISHAR, DIPCHANDDirector
AcquisitionCommon equity
16500 sharesClass A Common Stock
Not reportedContext evidence
RO, ISAACDirector
AcquisitionOptions and derivatives
18750 sharesStock Option (right to buy)
Not reportedContext evidence
RO, ISAACDirector
AcquisitionCommon equity
12375 sharesClass A Common Stock
Not reportedContext evidence
ROELOFS, NICOLAS H PHDDirector
AcquisitionCommon equity
16500 sharesClass A Common Stock
Not reportedContext evidence
ROELOFS, NICOLAS H PHDDirector
AcquisitionOptions and derivatives
25000 sharesStock Option (right to buy)
Not reportedContext evidence
NISHAR, DIPCHANDDirector
DisposalCommon equity
10660 sharesClass A Common Stock
$23.3KDirectional evidence
HORN, DAVID R.PRESIDENT & CFO
DisposalCommon equity
7303 sharesClass A Common Stock
$12.4KDirectional evidence
BAZARKO, ANTHONY R.Chief Commercial Officer
AcquisitionOptions and derivatives
225000 sharesEmployee Stock Option (right to buy)
Not reportedContext evidence
BAZARKO, ANTHONY R.Chief Commercial Officer
AcquisitionCommon equity
75000 sharesClass A Common Stock
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context